Lantheus Holdings Inc 2026年季度报告

(Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from __________ to __________Commission File Number 001-36569 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☑No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☑No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ The registrant had 65,106,082 shares of common stock, $0.01 par value, outstanding as of May 1, 2026. LANTHEUS HOLDINGS, INC.TABLE OF CONTENTS PagePART I. FINANCIAL INFORMATION1Item 1. Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets1Condensed Consolidated Statements of Operations2Condensed Consolidated Statements of Comprehensive Income3Condensed Consolidated Statements of Changes in Stockholders’ Equity4Condensed Consolidated Statements of Cash Flows5Notes to Condensed Consolidated Financial Statements7Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations33Item 3. Quantitative and Qualitative Disclosures About Market Risk48Item 4. Controls and Procedures48PART II. OTHER INFORMATION49Item 1. Legal Proceedings49Item 1A. Risk Factors49Item 2. Unregistered Sales of Equity Securities and Use of Proceeds52Item 3. Defaults Upon Senior Securities52Item 4. Mine Safety Disclosures52Item 5. Other Information52Item 6. Exhibits54SIGNATURES55 Lantheus Holdings, Inc.Condensed Consolidated Balance Sheets(Unaudited)(in thousands, except par value) The accompanying notes are an integral part of these condensed consolidated financial statements. Lantheus Holdings, Inc.Condensed Consolidated Statements of Operations(Unaudited)(in thousands, except per share data) Lantheus Holdings, Inc.Condensed Consolidated Statements of Comprehensive Income(Unaudited)(in thousands) Lantheus Holdings, Inc.Condensed Consolidated Statements of Changes in Stockholders’ Equity(Unaudited)(in thousands) Lantheus Holdings, Inc.Condensed Consolidated Statements of Cash Flows(Unaudited)(in thousands) Lantheus Holdings, Inc.Condensed Consolidated Statements of Cash Flows (Continued)(Unaudited)(in thousands) Lantheus Holdings, Inc.Notes to Condensed Consolidated Financial Statements(Unaudited) Note Regarding Company References and Trademarks Unless the context otherwise requires, references to the “Company,” “our Company,” “Lantheus,” “we,” “us” and “our” refer to LantheusHoldings, Inc. and its direct and indirect wholly-owned subsidiaries; references to “Lantheus Holdings” refer to Lantheus Holdings, Inc. and not toany of its subsidiaries; references to “Lantheus Medical” refer to Lantheus Medical Imaging, Inc., the wholly-owned subsidiary of LantheusHoldings; references to “Aphelion,” “Lantheus Alpha” and “Meilleur” refer to Aphelion LLC, Lantheus Alpha Therapy, LLC and MeilleurTechnologies, Inc., respectively, each a wholly-owned subsidiary of Lantheus Holdings; references to “Cerveau,” “Lantheus Real Estate,”“Progenics,” “Evergreen,” “Lantheus Radiopharm UK”, and “Lantheus Switzerland,” refer to Cerveau Technologies, Inc.; Lantheus MI RealEstate, LLC; Progenics Pharmaceuticals, Inc.; Evergreen Theragnostics, Inc.; Lantheus Radiopharmaceuticals UK Limited and LantheusSwitzerland GmbH, respectively, each a wholly-owned subsidiary of Lantheus Medical, references to “EXINI” refer to EXINI Diagnostics AB, awholly-owned subsidiary of Progenics, and references to “Lantheus Biosciences” refer to Lantheus Biosciences Ltd. (or to Life Molecular ImagingLimited prior to the Company’s acquisition of it in July 2025 and a name change in February 2026), a wholly-owned subsidiary of LantheusR